{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:47:30Z","timestamp":1767923250097,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.cmi.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T06:47:13Z","timestamp":1617259633000},"page":"958-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review"],"prefix":"10.1016","volume":"27","author":[{"given":"Charlotte","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Bottieau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora","family":"Buonfrate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Van Laethem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.03.004_bib1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.aau8225","article-title":"The reemergence of yellow fever","volume":"361","author":"Barrett","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cmi.2021.03.004_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jama.300.8.960","article-title":"Yellow fever: 100 years of discovery","volume":"300","author":"Staples","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2021.03.004_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/hv.4.4.5751","article-title":"Protective immunity following vaccination: how is it defined?","volume":"4","author":"Amanna","year":"2008","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.cmi.2021.03.004_bib4","first-page":"33","article-title":"Yellow fever fact sheet","volume":"85","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.cmi.2021.03.004_bib5","series-title":"Plotkin\u2019s vaccines","first-page":"1181","article-title":"Yellow fever vaccines","author":"Staples","year":"2017"},{"key":"10.1016\/j.cmi.2021.03.004_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/am.23.5.908-913.1972","article-title":"Yellow fever vaccine. V. Antibody response in maonkeys inoculated with graded doses of the 17D vaccine","volume":"23","author":"Mason","year":"1972","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.cmi.2021.03.004_bib8","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/blood-2010-05-285528","article-title":"B\u00a0cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy","volume":"116","author":"Moir","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2021.03.004_bib9","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1097\/00002030-200309260-00002","article-title":"Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection","volume":"17","author":"Lange","year":"2003","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.cmi.2021.03.004_bib10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-011110-130254","article-title":"Pathogenic mechanisms of HIV disease","volume":"6","author":"Moir","year":"2011","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/COH.0000000000000228","article-title":"Immune activation during acute HIV infection and the impact of early antiretroviral therapy","volume":"11","author":"Krebs","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.cmi.2021.03.004_bib13","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.4049\/jimmunol.1701615","article-title":"Early antiretroviral therapy preserves functional follicular helper T and HIV-specific B cells in the gut mucosa of HIV-1-infected individuals","volume":"200","author":"Planchais","year":"2018","journal-title":"J\u00a0Immunol (Baltim MD)"},{"key":"10.1016\/j.cmi.2021.03.004_bib14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1084\/jem.20181124","article-title":"Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells","volume":"216","author":"Liechti","year":"2019","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cmi.2021.03.004_bib15","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2019.01787","article-title":"Remembrance of things past: long-term B cell memory after infection and vaccination","volume":"10","author":"Palm","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2021.03.004_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2021.03.004_bib18","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.cmi.2021.03.004_bib19","series-title":"Meta-analysis with R","author":"Schwarzer","year":"2015"},{"key":"10.1016\/j.cmi.2021.03.004_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00002030-200403260-00020","article-title":"Yellow fever vaccine is safe and effective in HIV-infected patients","volume":"18","author":"Tattevin","year":"2004","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.cmi.2021.03.004_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/597006","article-title":"Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients","volume":"48","author":"Veit","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/157016210793499277","article-title":"Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients","volume":"8","author":"Pistone","year":"2010","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.cmi.2021.03.004_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/QAI.0b013e318249de59","article-title":"Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients","volume":"59","author":"Pacanowski","year":"2012","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2021.03.004_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.trstmh.2012.04.002","article-title":"Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali","volume":"106","author":"Sidibe","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.cmi.2021.03.004_bib25","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2015.07.036","article-title":"Diphtheria, tetanus, poliomyelitis, yellow fever and hepatitis B seroprevalence among HIV1-infected migrants. Results from the ANRS VIHVO vaccine sub-study","volume":"33","author":"Mullaert","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.03.004_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005219","article-title":"CD4\/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients","volume":"10","author":"Avelino-Silva","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/cix960","article-title":"Long-term immune response to yellow fever vaccination in human immunodeficiency virus (HIV)-infected individuals depends on HIV RNA suppression status: implications for vaccination schedule","volume":"66","author":"Veit","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib28","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1097\/QAD.0000000000001963","article-title":"Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients","volume":"32","author":"Colin de Verdiere","year":"2018","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.cmi.2021.03.004_bib29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/00006454-199712000-00015","article-title":"Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1","volume":"16","author":"Sibailly","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2021.03.004_bib30","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1086\/314031","article-title":"Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases","volume":"31","author":"Receveur","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/QAI.0000000000000845","article-title":"CD4\/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients","volume":"71","author":"Avelino-Silva","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2021.03.004_bib32","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","article-title":"Collaborative group for studies on yellow fever vaccines. Duration of post-vaccination immunity against yellow fever in adults","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.03.004_bib33","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2021.03.004_bib34","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1016\/j.vaccine.2019.05.048","article-title":"Collaborative group for studies on yellow fever vaccines. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.03.004_bib35","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.16-0401","article-title":"A\u00a0Meta-analysis of serological response associated with yellow fever vaccination","volume":"95","author":"Jean","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2021.03.004_bib36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2021.03.004_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/infdis\/jiz679","article-title":"Early antiretroviral therapy may preserve vaccine responses in HIV infected patients by preventing damage to long-lived plasma cells","volume":"222","author":"Nilsson","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib38","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3201\/eid2508.181432","article-title":"17DD yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil","volume":"25","author":"Campi-Azevedo","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149871","article-title":"A\u00a0single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination","volume":"11","author":"Wieten","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.cmi.2021.03.004_bib40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41598-017-00798-1","article-title":"Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination","volume":"7","author":"Kongsgaard","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2021.03.004_bib41","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1172\/JCI75429","article-title":"Immune activation alters cellular and humoral responses to yellow fever 17D vaccine","volume":"124","author":"Muyanja","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2021.03.004_bib42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2021.03.004_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4269\/ajtmh.1963.12.230","article-title":"Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine","volume":"12","author":"Rosenzweig","year":"1963","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2021.03.004_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J\u00a0Travel Med"},{"key":"10.1016\/j.cmi.2021.03.004_bib45","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1473-3099(10)70116-X","article-title":"Do children infected with HIV receiving HAART need to be revaccinated?","volume":"10","author":"Sutcliffe","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib46","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.1073\/pnas.0901702106","article-title":"Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children","volume":"106","author":"Pensieroso","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2021.03.004_bib47","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1097\/QAD.0000000000002246","article-title":"Perinatal HIV and response to vaccination","volume":"33","author":"Dauby","year":"2019","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.cmi.2021.03.004_bib48","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1473-3099(19)30323-8","article-title":"Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study","volume":"19","author":"Domingo","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2021.03.004_bib49","first-page":"CD010929","article-title":"Yellow fever vaccine for patients with HIV infection","volume":"1","author":"Barte","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2021.03.004_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/QAD.0000000000002092","article-title":"Growing up with perinatal HIV","volume":"33","author":"Flynn","year":"2019","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.cmi.2021.03.004_bib51","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1542\/peds.2005-2616","article-title":"Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection","volume":"118","author":"Bekker","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2021.03.004_bib52","doi-asserted-by":"crossref","first-page":"C61","DOI":"10.1016\/j.vaccine.2012.02.040","article-title":"Immunising the HIV-infected child: a view from sub-Saharan Africa","volume":"30","author":"Mphahlele","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.03.004_bib53","first-page":"269","article-title":"Vaccines and vaccination against yellow fever. WHO position paper\u2014june 2013","volume":"88","year":"2013","journal-title":"Wkly Epidemiol Rec"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21001397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21001397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:28:52Z","timestamp":1761118132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21001397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1198743X21001397"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.03.004","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}